As many Americans start the summer stressed about their physiques and health, there are important developments. Drug-makers report successful mid-stage trials for oral compounds that could soon join the injectable prescription medication to treat obesity that’s already on the market.
Dr. Jamy Ard, president-elect of The Obesity Society, says he believes oral obesity medications offer new options for those not comfortable with an injectable drug and for those who suffer adverse side effects from current offerings. He also believes more choices will lower prices for consumers.
“I think we’re at a watershed moment, this is really sort of an inflection point if you will, in thinking about the potential change in the landscape and how we conceptualize treatment of obesity. For the longest [time], a lot of the basic thinking about how we treat obesity was rooted in it was just a calorie imbalance…people were eating too much and exercising too little. As you know, that clearly has not worked,” says Dr. Ard.
He shares more insights on “Conversations on Health Care” with hosts Mark Masselli and Margaret Flinter.
Podcast: Play in new window | Download
Subscribe: Apple Podcasts | Spotify | Android | Podchaser | TuneIn | RSS | More
As we mark Earth Day, we have just experienced the hottest March on record. But…
What happens when music therapists and neuroscientists team up? Patients win, says Dr. Francis Collins.…
Originally published April 9, 2024 She’s received worldwide praise for singing at the Super Bowl,…
Originally published April 4, 2024 It’s about seven months to election day and our regular…
Originally published March 28, 2024 Medicare just announced that it will pay for weight loss…
The recent death of former college football player Craig Roh from colon cancer at age…